Which pharmaceutical company manufactures brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib) is a targeted therapy drug specifically used to treat ALK (anaplastic lymphoma tyrosine kinase)-positive non-small cell lung cancer (NSCLC). The drug is produced by Takeda Pharmaceutical Company, a leading global pharmaceutical company. Takeda Pharmaceutical was founded in 1781 and is headquartered in Japan. It is an international biopharmaceutical company that conducts drug research and development and production in many countries and regions around the world.

Takeda Pharmaceuticals is known for its innovative treatment options and high-quality medicines, especially in oncology, gastroenterology, neuroscience and other fields. The launch of brigatinib marks a major advance for Takeda Pharmaceuticals in the field of cancer treatment, especially its important contribution in the treatment of non-small cell lung cancer.

Brigatinib was approved by the US FDA (Food and Drug Administration) in 2017 for the treatment of metastatic ALK-positive non-small cell lung cancer that has spread to other parts of the body. The drug is approved as a second-line treatment for patients who are resistant or intolerant to crizotinib. The R&D and production of brigatinib are a reflection of Takeda Pharmaceutical's continuous innovation in the anti-cancer field. Through its strong R&D capabilities and global market network, brigatinib can quickly enter and be widely used in clinical treatments around the world.

As a second-generation ALK inhibitorBrigatinib has the advantage of being different from other ALK inhibitors in that it can effectively combat multiple mutations, especially ALK-positive patients who are resistant to crizotinib. Its mechanism of action can not only inhibit ALK kinase, but also effectively cross the blood-brain barrier, so it is particularly effective for patients with ALK-positive lung cancer with brain metastasis. Through continuous innovation, Takeda Pharmaceutical has made brigatinib an important drug in the anti-cancer field, helping more and more lung cancer patients achieve effective disease control and significantly improving their survival.

Reference materials:https://www.alunbrig.com/